PD-1 and PD-L1 Inhibitors Market
Global Industry Analysis and Forecast 2023-2030
Market Value (2022)
USD 38.20 Billion
Forecasted Value (2030)
USD 167.97 Billion
CAGR (2023 - 2030)
Fastest Growing Region (2023 - 2030)
By Inhibitor Type
Non-Small Cell Lung Cancer, Melanoma of the Skin, Head and Neck Cancers, Hodgkin Lymphoma, Kidney Cancer, Others
The global PD-1 and PD-L1 Inhibitors Market was valued at USD 38.20 billion in 2022 and is projected to reach USD 167.97 billion by 2030, growing at a CAGR of 20.77% from 2023 to 2030.
The global market for PD-1 and PD-L1 inhibitors can be characterized as a dynamic and rapidly growing sector of the pharmaceutical industry. The emergence of these checkpoint inhibitors has transformed cancer treatment by reactivating the mechanism of T-cells has shown promising results in clinical trials. Recent reports have shown that the COVID-19 pandemic has impacted this market. However, the market is expected to recover and grow substantially during 2023–2030.
North America and Europe are among the major regions in the PD-1 and PD-L1 inhibitors market. These regions account for a significant market share due to the high prevalence of cancer and the availability of advanced healthcare infrastructure. Moreover, the approval of new indications and increasing government support for cancer research have further boosted market growth in these regions.
Analyst’s Review on PD-1 and PD-L1 Inhibitors Market
The global market for PD-1 and PD-L1 inhibitors is a highly competitive and continuously evolving sector of the pharmaceutical industry. The market is characterized by significant ongoing research and development efforts aimed at expanding the range of applications for these checkpoint inhibitors in cancer treatment. North America, Asia-Pacific, and Europe are the prominent regions that are likely to experience exponential growth during 2023-2030.
PD-1/PD-L1 inhibitors are a class of checkpoint inhibitors that are immune checkpoint inhibitors and that have demonstrated efficacy as a first-line treatment option for various types of cancer. These proteins play a vital role in regulating immune responses and ultimately contribute to the body's ability to fight against diseases, including cancer. Normally, the binding of PD-L1 to PD-1 inhibitors keeps T cells from attacking and killing tumor cells. However, the use of immune checkpoint inhibitors that block PD-L1 to PD-1’s binding, such as anti-PD-1 or anti-PD-L1 medications, can effectively reactivate T cells' ability to attack and destroy tumor cells. The mechanism of action for immune checkpoint inhibitors has shown promising results in clinical trials, and the use of these medications has emerged as a novel and effective approach to cancer treatment and therapy. The PD-1/PD-L1 inhibitors market has emerged as a key part of the pharmaceutical industry in recent years. This market comprises drugs and therapies designed to modulate the PD-1/PD-L1 signaling pathways.
The global market for PD-1 and PD-L1 inhibitors has been driven by the increasing prevalence of cancer worldwide. Additionally, there has been a combined use of all approved checkpoint inhibitors as a means of enhancing the effectiveness of the treatment. Ongoing research and development efforts are aimed at expanding the range of applications for PD-1 and PD-L1 inhibitors in cancer therapy, and this has resulted in promising clinical trial results that have encouraged further investment in the development of these inhibitors.
However, a few factors could challenge the growth or expansion of the market such as the potential impact of adverse reactions relating to the immune protein on patient outcomes. This has limited the clinical application of the protein monoclonal antibodies despite their promising curative effects. Additionally, the high cost of PD-1 and PD-L1 inhibitors is a significant restraint, as it limits their accessibility for many patients. Furthermore, emerging immunotherapies and the increasing focus on personalized medicine may pose a challenge to the growth of the market, as it will create a threat of substitutes for PD-1 and PD-L1 inhibitors.
The global PD-1 and PD-L1 inhibitors market is segmented based on inhibitor type, application, and geography.
Based on inhibitor type, the market is further categorized into PD-1 and PD-L1. In 2022, the PD-1 category dominated the segment type by attributing more than 85% of the revenue. This dominance is attributed to several factors, such as a greater volume of research activities, approvals, and an increase in the number of prescriptions for drugs like nivolumab and pembrolizumab. Advancements in R&D are the prominent factor, as more efficient inhibitors are developed. However, PD-L1 is anticipated to exhibit a slightly higher growth rate compared to the PD-1 category. It is estimated that the PD-L1 category will experience a growth rate of 20.91% during the period of 2023-2030.
Based on application, the market is further categorized into non-small cell lung cancer, melanoma of the skin, head & neck cancers, kidney cancer, Hodgkin lymphoma, and others. In 2022, non-small cell lung cancer dominated the market, primarily attributed to a significant rise in drug approvals for the treatment of various solid tumors during the preceding four years. Notably, the market has also witnessed a surge in research for urogenital cancer treatments, as well as multiple approvals for technological advancements in the treatment of various cancers. These factors have collectively contributed to the rapid growth of this segment. Non-small cell lung cancer category is estimated to reach a revenue value of USD 61.11 billion by 2030 at a CAGR of 21.17%. Applications of PD-1 or PD-L1 for melanoma of the skin is anticipated to experience the highest CAGR of 23.19% during 2023-2030.
Based on regional analysis, the global PD-1 and PD-L1 inhibitors market is classified into North America, Europe, Asia-Pacific, MEA, and Latin America.
North America dominated the regional share in terms of market value, accounting for USD 14.60 billion and a global share of 38.22% in 2022. The dominance is attributable to the developed state of healthcare infrastructure and encouragement programs by governments to further develop the characteristics of inhibitors to gain control over the prevalence of cancer and other diseases. The presence of top players is another factor driving the market in the region. The U.S. is the most prominent country in the region and is estimated to reach a market value of USD 14.09 billion in 2023. Canada is anticipated to observe a significant growth rate of more than 19.18% during 2023–2030.
Asia-Pacific is estimated to reach a market value of USD 50.91 billion by 2030, with the highest anticipated growth rate of 23.69% during 2023–2030. By 2030, Asia-Pacific is likely to account for the second-largest regional share in terms of market value and revenue. China and India observe the highest growth rates at 26.40% and 23.80%, respectively. Development in the healthcare and pharmaceutical industries is the key factor supporting regional growth.
The global PD-1 and PD-L1 inhibitors industry study report will provide valuable insight with an emphasis on the global market, which is highly fragmented. Major players are focusing on a few of the strategies, such as partnerships, mergers and acquisitions, product innovations, and joint ventures, to expand their product portfolios and increase their respective market shares across different regions. Development and investments involve investments in R&D, new manufacturing facilities, and supply chain optimization. The major players in the PD-1 and PD-L1 inhibitors market are
- Merck & Co., Inc.,
- Hoffmann-La Roche Ltd,
- Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- Novartis AG
- BeiGene LTD.
- Bristol Myers Squibb (BMS)
- April 2023 (Acquisition) – Prometheus Biosciences, Inc. and Merck signed an agreement that is definitive of the acquisition of Prometheus Biosciences, Inc., by a subsidiary of Merck. The valuation is calculated at approximately USD 10.8 billion.
- August 2022 (Acquisition) – Turning Point Therapeutics, Inc., was acquired by Bristol-Myers Squibb in an all-cash transaction. The high experience of Turning Point in the field of oncology and the expansion of the portfolio for Bristol Myers Squibb was stated as one of the motives for the acquisition.
The global PD-1 and PD-L1 Inhibitors Market is segmented as:
By Inhibitor Type
- Non-Small Cell Lung Cancer
- Melanoma of the Skin
- Head and Neck Cancers
- Hodgkin Lymphoma
- Kidney Cancer
- North America
- Rest of Europe
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- North Africa
- South Africa
- Rest of Middle East & Africa
- Latin America
- Rest of Latin America